Plus Therapeutics reports positive Phase 1 trial results for Rhenium (186Re) Obisbemeda in breast cancer-related leptomeningeal disease.Quiver AI SummaryPlus Therapeutics, Inc. has shared promising results...
Plus Therapeutics renews agreement with Telix IsoTherapeutics for cGMP Re-186 supply, supporting clinical trial demands for cancer therapy.Quiver AI SummaryPlus Therapeutics, Inc. has renewed its Master...
Rhenium (186Re) Obisbemeda shows promising results for leptomeningeal metastases, with favorable survival rates and FDA trial approval.Quiver AI SummaryPlus Therapeutics, Inc. announced the positive results...
CNSide Diagnostics presents findings on mutational changes in CSF for leptomeningeal metastases, aiding treatment selection.Quiver AI SummaryCNSide Diagnostics, a subsidiary of Plus Therapeutics, presented...